JAKAFI® (ruxolitinib)

April 24, 2023

JAKAFI® (ruxolitinib)

Onco360®, the nation’s leading independent specialty pharmacy, has been selected by Incyte as a specialty pharmacy partner for JAKAFI® (ruxolitinib). JAKAFI® is a kinase inhibitor indicated for treatment of1:

  • intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis in adults
  • polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea
  • steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older
  • chronic graft-versus-host disease after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older

JAKAFI®  (ruxolitinib) was initially approved by the U.S. Food and Drug Administration (FDA) on November 16, 2011, for Myelofibrosis based on results from two randomized Phase III trials COMFORT-I and COMFORT-II2. For more information go to www.jakafi.com.



1JAKAFI® prescribing information www.jakafi.com. Accessed 4/23. JAKAFI is a registered trademark of Incyte. All rights reserved.